{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-006116","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.544991+00:00","generated_at":"2026-05-16T01:39:03.041822+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Insmed reports FY2025 revenue $606M (+67% YoY); guides BRINSUPRI to at least $1B in FY2026","bullets":["Full-year 2025 total revenues $606.4M (+67% YoY); ARIKAYCE $433.8M (+19%), BRINSUPRI $172.7M since Aug launch.","Guides FY2026 BRINSUPRI revenue ≥$1B, ARIKAYCE $450-470M; net loss $1,276.8M ($6.42/share) vs $913.8M in 2024.","Cash & equivalents ~$1.4B; plans to fund pipeline including ENCORE, CEDAR, TPIP Phase 3, and gene therapy programs.","Director David W.J. McGirr will not stand for re-election at 2026 annual meeting, no disagreement with company."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-006116","json":"https://secwatch.observer/filing/0001140361-26-006116.json","markdown":"https://secwatch.observer/filing/0001140361-26-006116.md","text":"https://secwatch.observer/filing/0001140361-26-006116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/0001140361-26-006116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036126006116/ef20066055_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:39:03.041822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}